# BIOSPECIFICS TECHNOLOGIES CORP

BIOSPECIFICS TECHNOLOGIES CORP is a company headquartered in Lynbrook, NY, United States.

## Company overview

- **Legal name:** BIOSPECIFICS TECHNOLOGIES CORP
- **Classification:** Company
- **Industry (SIC):** 2834 — Pharmaceutical Preparations
- **Headquarters:** Lynbrook, NY, United States
- **Incorporated in:** DE
- **Fiscal year end:** December 31
- **SEC CIK:** 0000875622

## About

BIOSPECIFICS TECHNOLOGIES CORP is identified in the retained SEC EDGAR snapshot dated 2026-10-14. Its SEC Central Index Key is 0000875622, and its reported industry is Pharmaceutical Preparations. In 10-K filed on 2020-03-16, it reported annual revenue of USD 38,187,755; net income of USD 24,469,808; total assets of USD 126,653,268 for the fiscal period ended 2019-12-31. The financial history preserves reporting periods, currencies, filing accessions and source provenance. Figures are reported filing data, rather than real-time estimates.

## Financials

Annual figures as originally reported. Currency is shown for each fiscal year; B means billion and M means million.

### FY2019 (period ended 2019-12-31)

- **Revenue:** $38.2M (USD 38,187,755)
- **Net income:** $24.5M (USD 24,469,808)
- **Total assets:** $126.7M (USD 126,653,268)
- **Cash and equivalents:** $5.0M (USD 4,999,183)
- **Operating cash flow:** $22.3M (USD 22,285,149)

### FY2018 (period ended 2018-12-31)

- **Revenue:** $33.0M (USD 32,961,443)
- **Net income:** $20.1M (USD 20,053,269)
- **Total assets:** $100.1M (USD 100,092,042)
- **Cash and equivalents:** $13.2M (USD 13,176,452)
- **Operating cash flow:** $17.7M (USD 17,730,536)

### FY2017 (period ended 2017-12-31)

- **Revenue:** $27.4M (USD 27,443,752)
- **Net income:** $11.3M (USD 11,328,266)
- **Total assets:** $75.0M (USD 74,996,394)
- **Cash and equivalents:** $7.3M (USD 7,333,810)
- **Operating cash flow:** $13.2M (USD 13,157,654)

### FY2016 (period ended 2016-12-31)

- **Revenue:** $26.3M (USD 26,250,955)
- **Net income:** $11.4M (USD 11,372,239)
- **Total assets:** $64.7M (USD 64,696,280)
- **Cash and equivalents:** $4.8M (USD 4,763,364)

## Recent SEC filings

- Form 8-K — filed 2020-12-02 — period 2020-12-02 — FORM 8-K
- Form 10-Q — filed 2020-11-09 — period 2020-09-30 — 10-Q
- Form 8-K — filed 2020-11-09 — period 2020-11-09 — FORM 8-K
- Form SC 13D — filed 2020-10-30 — SC 13D
- Form SC 13D — filed 2020-10-29 — SC 13D
- Form 8-K — filed 2020-10-19 — period 2020-10-19 — FORM 8-K
- Form 8-K — filed 2020-09-14 — period 2020-09-14 — FORM 8-K
- Form 8-K — filed 2020-08-31 — period 2020-08-31 — FORM 8-K
- Form 8-K — filed 2020-08-11 — period 2020-08-11 — FORM 8-K
- Form 10-Q — filed 2020-08-10 — period 2020-06-30 — 10-Q
- Form 8-K — filed 2020-08-10 — period 2020-08-10 — FORM 8-K
- Form 8-K — filed 2020-07-20 — period 2020-07-20 — FORM 8-K

---

Updated: 2026-10-23T20:13:49Z

Canonical page: https://altss.com/profile/biospecifics-technologies-corp

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology